Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wych, J; Brunner, M; Stenson, R; Chmura, PJ; Danne, T; Mander, AP; Mathieu, C; Dayan, C; Pieber, TR.
Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial.
BMJ Open. 2024; 14(11): e091597
Doi: 10.1136/bmjopen-2024-091597
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brunner Martina
- Pieber Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- INTRODUCTION: Type 1 diabetes mellitus (T1DM) is a disorder that arises following the selective autoimmune destruction of the insulin-producing beta cells. Beta-cell protective or beta-cell regenerative approaches have gained wider attention, and pharmacological approaches to protect the patient's own insulin-producing beta-cell mass have been proposed. Verapamil is an L-type calcium channel blocker that has been reported to effectively lowers beta-cell thioredoxin-interacting protein expression in rodent beta cells and islets, as well as in human islets, and thus promotes functional beta-cell mass. METHODS AND ANALYSIS: The trial is a multicentre, randomised, double-blind, placebo-controlled trial in participants with T1DM, investigating the effect of verapamil on preservation of beta-cell function (Ver-A-T1D). A total of 120 participants will be randomised in a 2:1 ratio between 360 mg verapamil and placebo, administered orally once daily. T1DM patients aged ≥18 and <45 years will be eligible for recruitment within 6 weeks of diagnosis (defined as day of starting insulin therapy). The primary objective will be to determine the changes in stimulated C-peptide response during the first 2 hours of a mixed meal tolerance test at baseline and after 12 months for 360 mg verapamil administered orally once daily versus placebo. Secondary objectives include the effects of 360 mg verapamil on (1) fasting C-peptide, (2) dried blood spot C-peptide, (3) glycated haemoglobin, (4) daily total insulin dose, (5) time in range by intermittent continuous glucose monitoring measures, (6) other biomarkers related to immunological changes and beta-cell death and (6) safety (vital signs, ECG). ETHICS AND DISSEMINATION: Ethics approval was sought from the research ethics committee of all participating countries. All participants provided written informed consent before joining the study. Ver-A-T1D received first regulatory and ethical approvals in Austria. The publication policy is set in the innovative approach towards understanding and arresting type 1 diabetes grant agreement (www.innodia.eu). TRIAL REGISTRATION NUMBER: EudraCT, 2020-000435-45; ClinicalTrials.gov, NCT04545151. PROTOCOL VERSION: Version 8.0 (08 November 2021).
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Diabetes Mellitus, Type 1 - drug therapy
- Verapamil - therapeutic use, pharmacology
- Double-Blind Method - administration & dosage
- Insulin-Secreting Cells - drug effects, metabolism
- Adult - administration & dosage
- Calcium Channel Blockers - therapeutic use, administration & dosage
- Multicenter Studies as Topic - administration & dosage
- Randomized Controlled Trials as Topic - administration & dosage
- Male - administration & dosage
- Female - administration & dosage
- Young Adult - administration & dosage
- Blood Glucose - drug effects, metabolism
- C-Peptide - blood
- Insulin - administration & dosage
- Adolescent - administration & dosage
- Glycated Hemoglobin - metabolism
- Middle Aged - administration & dosage
- Find related publications in this database (Keywords)
- DIABETES & ENDOCRINOLOGY
- Randomized Controlled Trial
- Clinical Trial